November 10, 2017
Today the Department of Transportation amended its drug-testing program regulation to add hydrocodone, hydromorphone, oxymorphone, and oxycodone to its drug-testing panel; add methylenedioxyamphetamine (MDA) as an initial test analyte; and remove methylenedioxyethylamphetamine (MDA) as a confirmatory test analyte.
The revision of the drug-testing panel harmonizes DOT regulations with the revised HHS Mandatory Guidelines established by the U.S. Department of Health and Human Services for Federal drug-testing programs for urine testing. This final rule clarifies certain existing drug-testing program provisions and definitions, makes technical amendments, and removes the requirement for employers and Consortium/Third Party Administrators to submit blind specimens.
This rule is effective on January 1, 2018.
To learn more about this final rule, visit ODAPC's web page at https://www.transportation.gov/odapc/Part_40_Final_Rule_Summary_of_Changes